| 词条 | Epratuzumab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 457119498 | image = | type = mab | mab_type = mab | source = zu/o | target = CD22 | tradename = LymphoCide | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Investigational | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 205923-57-5 | ATC_prefix = none | ATC_suffix = | PubChemSubstance = 47206001 | DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank = DB04958 | IUPHAR_ligand = 8088 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 3062P60MH9 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D04036 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | chemical_formula = | molecular_weight = }}Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).[1][2] Clinical trialsA clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results.[3] Results have been published for a phase II trial in untreated follicular lymphoma.[3] Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging.[3][3] The manufacturers in August 2009 announced success in early trials against SLE,[4] and started two Phase III clinical trials. July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.[5] Mechanism of actionEpratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells. Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system"[5] via a process called trogocytosis.[6] (Other SLE therapies destroy B-cells which compromises the immune system.) References1. ^Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research Vol. 9, September 1, 2003 free full text {{Monoclonals for immune system}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clinical Cancer Research Vol. 11, July 15, 2005 free full text 3. ^{{cite journal |url=http://www.bloodjournal.org/content/bloodjournal/118/15/4053.full.pdf |author= Micallef |title=Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. |journal=Blood |volume=118 |issue=15 |pages=4053–61 |doi=10.1182/blood-2011-02-336990 |year=2011|display-authors=etal|pmc=3204728 }} 4. ^Reuters: [https://www.reuters.com/article/pressRelease/idUS59586+27-Aug-2009+GNW20090827 UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)] 5. ^1 Epratuzumab flunks two Phase 3 studies; Immunomedics plummets 42% premarket. July 28 2015 6. ^1 2 3 Epratuzumab 1 : Monoclonal antibodies for tumors |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。